|

Capmatinib Clinical Trials

4 actively recruiting trials across 1 location

No change since May 2026

Also known as: INC-280, INC280, INCB 28060, INCB028060, INCB28060 +1 more

Pipeline

Phase 2: 1Phase 1/2: 1Phase 2/3: 2

Top Sponsors

  • Cancer Research UK2
  • SWOG Cancer Research Network1
  • Gustave Roussy, Cancer Campus, Grand Paris1

Indications

  • Cancer4
  • Solid Tumour2
  • Haematological Malignancy2
  • Recurrent Lung Non-Small Cell Carcinoma1
  • Neoplasms by Histologic Type1

Other3 trials

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Phase 2/3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Phase 2/3
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2

Daphne, Alabama1 trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.